The 4th edition of the SUDOE Program for the period 2014-2020 is open to two thematic priorities of the program (axis 1: Research and innovation and axis 5: Environment and resource efficiency), with an ERDF budget of 12.9 million euros, distributed as follows:
| Axis 1: Research and innovation | Axis 5: Environment and resource efficiency |
 |
 |
| 8.7 million euros | 4.2 million euros |
The projects must be developed by consortia formed by at least 3 of the countries of the SUDOE region (Spain, southern France, Portugal, Gibraltar and the Principality of Andorra). The proposals are presented in two phases, the first phase, which consists of a sample of interest of about 20 pages, is now open. Funding is 75% of the eligible costs.
The deadline for submission of applications is 10/25/2019
If you are interested in participating in this call, do not hesitate to contact the International Projects Office of IDIVAL and they will advise you.
Contact email: innovacion4@idival.org or proyectos1@idival.org
The 4th edition of the SUDOE Program for the period 2014-2020 is open to two thematic priorities of the program (axis 1: Research and innovation and axis 5: Environment and resource efficiency), with an ERDF budget of 12.9 million euros, distributed as follows: Axis 1: Research and innovation Axis 5: Environment and resource efficiency […]
In a recent publication in the prestigious journal The European Journal of Health Economics (JCR impact factor 2,169, quartile 1) under the title “Partner's depression and quality of life among older Europeans” three members of the R&D&i Group in Health Economics and Health Services Management UC-IDIVAL study how the mental health of the couple influences the individual welfare of the spouse.
Mental health is related, according to empirical evidence at the international level, to worse living conditions of the population, placing itself as one of the main items in the political agendas in recent times. In this way, in this research, the “splillover or externality” effects of mental health within European households are studied given their wide heterogeneity.
To carry out the study, Professors Pascual-Sáez, Cantarero-Prieto and Blázquez-Fernández consider a sample of couples (married, registered, or living together) of the Health, Aging and Retirement panel survey in Europe (in English SHARE). Specifically, they determine the impact that the couple's mental health has on the well-being of their spouse, in addition to analyzing the main characteristics of individual and sociodemographic health. The study is carried out for 18 European countries, showing clear differences between the Mediterranean countries (“family-type”) and non-Mediterranean countries.
The empirical findings corroborate that there is a significant “spillover or externality” effect of mental health within households (OR = 1.51, 95% C.I. 1.43, 1.59). In addition, respondents who work or those who live in rural areas would be less likely to report poor quality of life or well-being. At the same time, the age of the individual, self-perceived health and educational level would also be key factors in the future of the subject in terms of well-being.
In this way, the authors come to emphasize that there is a strong “empathy” between couples, regardless of whether a man or a woman is the interviewed subject. This is, once controlled by the traditional individual factors (age, education or employment status), the evidence available with thousands of data from European households shows the strong interdependence of the closest environment and reaffirms once again the “cushion” effect that has to the negative consequences of unwanted loneliness (already shown by these same authors in the article published in Plos ONE “Social isolation and multiple chronic diseases after age 50: A European macro-regional analysis“).
These findings of the R&D&I Group in Health Economics and Management of Health Services UC-IDIVAL are of fundamental importance for the design of public policies that consider the social perspective of well-being in general, as well as the mental health policy, in particular.
In a recent publication in the prestigious journal The European Journal of Health Economics (JCR impact factor 2,169, quartile 1) under the title “Partner's depression and quality of life among older Europeans” three members of the R&D&i Group in Health Economics and Health Services Management UC-IDIVAL study how the mental health of the couple influences the […]
On July 11th and 12th, 2019, a seminar will be held in Santander during the Summer Courses of the Menéndez Pelayo International University (UIMP by its initials in Spanish) on the Spanish Science, Technology and Innovation Strategy 2021-2027, which will be an opportunity to learn about the progress in defining this strategy, which will be key to the future of Science, Technology and Innovation in Spain.
It will be a participatory forum to collect ideas during the preparation of this strategic agenda, which is an excellent opportunity to participate.
Link to register for the course: http://www.uimp.es/agenda-linkb.html?id_actividad=64KK&anyaca=2019-20
Meeting UIMP 2019 – 11/12 of July
Spanish Strategy for Science, Technology and Innovation 2021-2027
Director: Teresa Riesgo Alcaide
Secretary: Inmaculada Bahón Arnaiz
Course program
Day 1:
9.30h: Welcome and opening of the course: Ángeles Heras Caballero, Secretary of State for Universities, Research, Development and Innovation of the Ministry of Science, Innovation and Universities (MCIU).
10.00 am: Conference: Elaboration of the Spanish Strategy of Science, Technology and Innovation 2021-2027; Teresa Riesgo Alcaide, General Director of R & D of the MCIU.
11.00h: Coffee
11.30h Roundtable: What does Spain need to improve its science and innovation system in the coming years?
Speakers:
Moderator: Cristina Moneo Ocaña, Deputy Director General of Planning, Monitoring and Evaluation.
13.30h Lunch
3:00 pm: Conference: Sustainable Development and R+D+i Objectives; Carlos Mataix, Director of IDT-UPM.
16: 00h: Roundtable: Science and Innovation as an economic and social engine.
Speakers:
Moderator: Gonzalo León, Chair of the UPM
Day 2:
9.30h: Conference: Horizon Europe; Román Arjona-Gracia, Chief Economist of the Directorate General for Research and Innovation, European Commission.
11.00: Coffee
11.30: Roundtable: National Strategies on Science and Innovation in an international environment.
Speakers:
Moderator: Eduard Alarcón, Professor at the UPC
13:30: Closure of the course: Teresa Riesgo Alcaide, General Director of R + D + I of the MCIU
On July 11th and 12th, 2019, a seminar will be held in Santander during the Summer Courses of the Menéndez Pelayo International University (UIMP by its initials in Spanish) on the Spanish Science, Technology and Innovation Strategy 2021-2027, which will be an opportunity to learn about the progress in defining this strategy, which will be […]
The first volume of the 5th edition of the series of the World Health Organization (WHO) on the classification of tumors in humans will be recently published. This series, known as the blue WHO books, is a reference for the diagnosis of neoplasms in different systems and It is an international standard for those involved in […]
Chronic Lymphatic Leukemia (CLL) is the most common type of leukemia in adults in the West. It mainly affects elderly patients and its incidence is expected to increase due to the progressive increase in life expectancy in our society. Today is an incurable disease, with a development that can be indolent or more aggressive. Knowing the molecular cause of this disease is essential to develop healing therapies.
Researchers of the group of hematological neoplasms and transplantation of hematopoietic progenitors of IDIVAL, led by Dr. Carlos Pipaón of the Molecular Hematology Laboratory (HEMMOL), have discovered that high levels of expression of the FANCA gene, involved in DNA repair, constitute a marker of worse prognosis in CLL. In the recently published work in the FASEB Journal (https://doi.org/10.1096/fj.201802439RR), also signed by the predoctoral student Sara Bravo, Dr. Lucrecia Yáñez and Dr. Íñigo Romón from the Hematology Service, analyzed the expression of this type of genes in samples of several hundred of patients of the hospital. This marker is associated with other factors of poor prognosis such as the deletion of the long arm of chromosome 11 and with a time from diagnosis to the shortest treatment. The group has investigated the molecular basis of this worse prognosis and has discovered that FANCA collaborates in the degradation of the p53 protein, involved in the protection of the genome and the response to chemotherapeutic agents, which leads to a greater proliferation of B lymphocytes of the CLL. The work reveals the importance that cellular processes that modify the function of proteins can have on the development and treatment of pathologies in which a genetic cause has not been identified.
Chronic Lymphatic Leukemia (CLL) is the most common type of leukemia in adults in the West. It mainly affects elderly patients and its incidence is expected to increase due to the progressive increase in life expectancy in our society. Today is an incurable disease, with a development that can be indolent or more aggressive. Knowing […]
Patients with solid organ transplants, due to the transplant process itself, hospital admission and immunosuppression, among other factors, are frequently colonized or infected by antibiotic resistant bacteria.
In a study published recently in the Scientific Reports journal [doi: 10.1038 / s41598-019-45060-y], IDIVAL researchers belonging to the group of Epidemiology and Pathogenic and Molecular Mechanisms of Infectious Diseases and Microbiology, led by Dr. Carmen Fariñas, Head of the Infectious Diseases Service of the Hospital Marqués de Valdecilla, have studied the virulence factors of a collection of bacteria isolated from transplanted patients (kidney, liver or liver-pancreas).
These bacteria, belong mainly to the species Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae and are able to colonize these patients and cause infections after the transplant surgery. Hence, it is very important to know their capacity to colonize, not only the digestive tract of patients, but also the surfaces and medical devices which they come into contact with. This is a serious problem, because all selected bacteria turned out to be resistant to multiple antibiotics. These are the so-called “Superbaceria” that may cause serious infections that are difficult to fight. One of the virulence factors analyzed has shown that the bacterium Klebsiella pneumoniae has a great capacity to form biofilms, which indicates that it could easily colonize human intestinal cells and resist antibiotics better. The more capacity to form biofilms, the longer these bacteria will remain in the intestine of patients and even in the hospital environment. This adherence capacity seems to be less important in E. coli and Enterobacter, so in these species other virulence factors may be involved in the colonization of patients and infections that occur after transplantation.
This study is part of the ENTHERE project, a project carried out in 7 hospitals and research centers throughout Spain, which aims to seek treatments to fight the Superbacteria that colonize and infect transplanted patients.
In the image a dividing bacterium of the Klebsiella pneumoniae species isolated from a transplanted patient is shown. The image has been taken at 20,000 magnifications in an electron microscope of the IDIVAL microscopy services.
Patients with solid organ transplants, due to the transplant process itself, hospital admission and immunosuppression, among other factors, are frequently colonized or infected by antibiotic resistant bacteria. In a study published recently in the Scientific Reports journal [doi: 10.1038 / s41598-019-45060-y], IDIVAL researchers belonging to the group of Epidemiology and Pathogenic and Molecular Mechanisms of […]
The European Commission has published the update of the Work Programs of the Horizon 2020 program for 2020. Among the Programs published the Social Challenge 1 can be found: Health, Demographic Change and Welfare through which they will be financed, with a budget of 660 million €, collaborative projects, complementary actions and coordination through different topics / themes.
Below you will find the links to the summary of the topics of the Social Challenge 1 (PROPOSAL IN 2 PHASES), which will be open from July 4 to September 24, 2019 at 5:00 pm:
SC1-BHC-08-2020 (RIA): New interventions for Non-Communicable Diseases.
SC1-BHC-24-2020 (RIA): Healthcare interventions for the management of the elderly multimorbid patient.
SC1-BHC-29-2020 (RIA): Innovative actions for improving urban health and wellbeing – addressing environment, climate and socioeconomic factors.
SC1-DTH-13-2020 (RIA): Implementation research for scaling up and transfer of innovative solutions involving digital tools for people-centered care.
If you are interested in participating in any of the topics of this call, do not hesitate to contact the International Projects Office of IDIVAL and they will advise you. Contact email: innovacion4@idival.org or proyectos1@idival.org
The European Commission has published the update of the Work Programs of the Horizon 2020 program for 2020. Among the Programs published the Social Challenge 1 can be found: Health, Demographic Change and Welfare through which they will be financed, with a budget of 660 million €, collaborative projects, complementary actions and coordination through different […]
The Call gives researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future.
Why apply?
IMI2 – Call 18
Read the topic texts: bit.ly/IMI2Call18
Deadline for short proposals: 26 September 2019
IMI2 – Call 18 was launched on 26 June 2019 and is a standard, two-stage Call for proposals. It includes the following topics:
How to apply
About the Innovative Medicines Initiative
At IMI, they are working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.
They do this by facilitating collaboration between the key players involved in healthcare research.
They are a partnership between the European Union and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations), and have a €3.3 billion budget for the period 2014-2020.
Since their launch in 2008, they have launched over 100 projects in areas as diverse as dementia, pain, diabetes, autoimmune disease and antimicrobial resistance as well as tools for drug discovery and development, clinical trial design, and drug and vaccine safety.
Stay in touch
Visit the IMI website: www.imi.europa.eu
For further information about the call, please contact innovacion4@idival.org or proyectos1@idival.org
The Call gives researchers from diverse sectors the opportunity to participate in ambitious public-private partnerships that will pave the way for the development of the medicines of the future. Why apply? Obtain research funding Take part in scientifically excellent, patient-centric research Join unique consortia involving top teams from industry, academia, SMEs, regulators, and others Benefit […]
Last May, the British journal “Nuclear Medicine Communications” published the work entitled “A 5-year longitudinal evaluation in patients with mild cognitive impairment by 11C-PIB PET / CT: a visual analysis” that gathers results of the longitudinal study that the Service of Nuclear Medicine of the University Hospital Marqués de Valdecilla (HUMV) and the Molecular Imaging group of IDIVAL (in collaboration with the Cognitive Impairment Unit of the Neurology Service) has been carrying out during the development of the FISS PI/01656 project. In addition, the journal has distinguished it by choosing for its cover, the cerebral PET images showed in the work.
The cerebral cortical deposit of β-amyloid protein has been postulated as the disturbing event that may be at the origin of the changes that lead to the synaptic dysfunction and cerebral degeneration of Alzheimer's disease. These initial phenomena have been monitored “in vivo” due to the development of radiotracers with high affinity for β-amyloid, among which the B of Pittsbourgh compound marked with Carbon 11 (11C-PIB) stands out as reference. The Radiopharmacy Unit of the Nuclear Medicine service of the HUMV is the only Spanish center that synthesizes this radiotracer, authorized by the Spanish Medicines and Medical Devices Agency.
Not all cognitive impairments are due to Alzheimer's disease, and even when correctly identified, patients do not evolve the same. Identifying those individuals with different paths is very important for the research of therapies or individualized preventive strategies. Thus, it has recently been described under the acronym LATE (Limbic-predominant age-related TDP-43 encephalopathy) a type of degenerative frame so far confused with Alzheimer's disease, which may not respond to the same therapeutic targets as this disease, and with differential characteristics in the molecular image. Characterizing and knowing the neurobiological substrate is the necessary primary step to deal with the disease correctly. This is where the value and transcendence of the evolutionary study that is being carried out in this project is focused.
The project entitled “Evolutionary study at 5 years in a population with Mild Cognitive Impairment (MCI) previously evaluated with 11C-PIB and 18F-FDG PET / CT” led by Dr. Jiménez Bonilla of the Service of Nuclear Medicine of the HUMV has been developed for two years, with the collaboration of patients and relatives. In the published work, topographic patterns of amyloid brain deposition and its association with clinical evolution are identified. It is in the frontal, temporo-parietal and basal ganglia region where the variations of this deposit are mainly appreciated.
Currently, the evaluation of amyloid deposit variations is being combined with the information on cerebral metabolism of previous and evolutive glucose, taking into account neuropsychological profiles and demographic and biochemical factors. In that sense, initial results have also been communicated. We trust that this knowledge will help reduce the burdens that these diseases pose for patients and their families.
Last May, the British journal “Nuclear Medicine Communications” published the work entitled “A 5-year longitudinal evaluation in patients with mild cognitive impairment by 11C-PIB PET / CT: a visual analysis” that gathers results of the longitudinal study that the Service of Nuclear Medicine of the University Hospital Marqués de Valdecilla (HUMV) and the Molecular Imaging […]
Within the framework of the XIIth Inter-regional Health Meeting organized at the Menéndez Pelayo International University by Joaquín Cayón, Head of Legal Services of the Ministry of Health of the Government of Cantabria, and Jorge Tomillo, Professor of Commercial Law of the University of Cantabria; the Health Counselor, María Luisa del Real has granted Dr. Valentín Fuster with the Prize for the International Research Experience in the Field of the Right to Health.
Dr. Fuster has numerous achievements, some of which are worth noting:
Awards of maximum global relevance, including the Prince of Asturias Research Award and the Great Scientific Award of the Institute of France; he has also been named Doctor Honoris Causa at 34 prestigious Universities (including the Menéndez Pelayo International University in 2010), has received the highest research awards from the main international organizations of Cardiology and has been Co-Director of the Committee that developed the report named “Global Health and the Future Role of the United States”.
As a result of his excellent research activity in the field of Cardiology and health, Dr. Fuster has published more than 900 scientific articles in international medical journals and scientific books.
Among the many positions and responsibilities performed by Dr. Fuster, the following may be highlighted: Managing Director of the Carlos III National Center for Cardiovascular Research (CNIC) of Madrid; Director of the Cardiovascular Institute and “Physician-in-Chief”, of the Mount Sinai Medical Center of New York; President of the American Heart Association; President of the World Heart Federation; Member of the Institute of Medicine of the American National Academy of Sciences; Member of the Advisory Council of the American Institute “National Heart, Lung and Blood Institute” and President of the Training Program of the American College of Cardiology.
Dr. Valentin Fuster is currently the most cited Spanish researcher of all time, in addition to the fact of being the only doctor in the world who has a puppet of the Sesame Street show – Dr. RUSTER – who shares show with our beloved ERNIE, BERT, GROVER, KERMIT THE FROG and THE COOKIE MONSTER, a fact that illustrates his great interest in our society's cardiovascular health and his contribution, in a very relevant way, to encourage healthy habits among the youngest population.
Within the framework of the XIIth Inter-regional Health Meeting organized at the Menéndez Pelayo International University by Joaquín Cayón, Head of Legal Services of the Ministry of Health of the Government of Cantabria, and Jorge Tomillo, Professor of Commercial Law of the University of Cantabria; the Health Counselor, María Luisa del Real has granted Dr. […]
